Drug Profile

NK 611

Latest Information Update: 21 Aug 2007

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Nippon Kayaku
Class Antineoplastics; Lignans; Tetrahydronaphthalenes
Mechanism of Action DNA inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Cancer; Solid tumours

Most Recent Events

02 Oct 2001 No-Development-Reported for Solid tumours in Japan (PO)
20 Jul 1999 A clinical study has been added to the therapeutic trials, adverse events and pharmacokinetics sections
01 Dec 1997 Suspended-I for Cancer in Germany (PO)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com